Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: First description of Candida nivariensis in Argentina.
The presence of the cryptic species belonging to the Candida glabrata complex has not been studied in Argentina. We analyzed a collection of 117 clinical isolates of C. glabrata complex belonging to a National Culture Collection of Instituto Nacional de Microbiología "Dr. Carlos G. Malbrán" from Argentina (40 isolates from blood samples, 18 from other normally sterile sites, 20 from vagina, 14 from urine, 7 from oral cavity, 3 from catheter, 1 from a stool sample and 14 isolates whose clinical origin was not recorded). The aims of this work were to determine the prevalence of the cryptic species Candida nivariensis and Candida bracarensis and to evaluate the susceptibility profile of isolates against nine antifungal drugs. Identification was carried out by using classical phenotypic tests, CHROMagar™ Candida, PCR and MALDI-TOF. The minimal inhibitory concentrations of amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, voriconazole, ketoconazole, posaconazole, caspofungin and anidulafungin were determined according to the EDef 7.3 (EUCAST) reference document. Of the 117 isolates, 114 were identified as C. glabrata and three as C. nivariensis by using PCR and MALDI-TOF. There were no major differences between C. nivariensis and C. glabrata susceptibility profiles. No resistant strains were found to echinocandins. We have found that the percentage of C. nivariensis in our culture collection was 2.56. This is the first description of C. nivariensis in Argentina, and data obtained could contribute to the knowledge of the epidemiology of this cryptic species.
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina.
Soraya Eugenia
SE
Morales-López
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina.
Constanza G
CG
Taverna
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina.
María Eugenia
ME
Bosco-Borgeat
Laboratorios Domeq y Lafage, Ciudad Autónoma de Buenos Aires, Argentina.
Ivana
I
Maldonado
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina.
Walter
W
Vivot
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina.
Wanda
W
Szusz
Laboratorio de Micología y Diagnóstico Molecular, Cátedra de Parasitología y Micología, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina.|Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Santa Fe, Argentina.
Guillermo
G
Garcia-Effron
Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Avenida Vélez Sarsfield 563, Ciudad Autónoma de Buenos Aires, Argentina. sorayaeugeniam@hotmail.com.
Susana B
SB
Córdoba
D000935:Antifungal Agents / Q000494:pharmacology*; D001118:Argentina / Q000453:epidemiology; D041221:Candida glabrata / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification*; D002177:Candidiasis / Q000453:epidemiology* / Q000382:microbiology*; D003470:Culture Media; D006801:Humans; D008828:Microbiological Techniques; D025202:Molecular Diagnostic Techniques; D016133:Polymerase Chain Reaction; D015995:Prevalence; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D000935:Antifungal Agents; D003470:Culture Media
Antifungal susceptibility testing; Candida bracarensis; Candida glabrata complex; Candida nivariensis; MALDI-TOF; Yeast identification
J Clin Microbiol. 2007 Oct;45(10):3459-61
17652473
Mem Inst Oswaldo Cruz. 2013 Apr;108(2):178-85
23579797
Mycoses. 2013 May;56(3):394-6
23170902
Asian Pac J Trop Biomed. 2014 Aug;4(8):659-62
25183337
J Clin Microbiol. 2008 Mar;46(3):933-8
18199788
Diagn Microbiol Infect Dis. 2013 May;76(1):46-50
23537782
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
23137135
J Clin Microbiol. 2009 Apr;47(4):1216-7
19193845
J Clin Microbiol. 2008 Oct;46(10):3498-500
18685009
J Clin Microbiol. 2005 Aug;43(8):4107-11
16081957
J Clin Microbiol. 2011 Sep;49(9):3375-9
21752976
Mycopathologia. 2014 Oct;178(3-4):279-83
25118875
Mem Inst Oswaldo Cruz. 2016 Jan;111(1):51-8
26814644
Med Mycol. 2011 Jul;49(5):525-9
21198347
J Clin Microbiol. 2011 Apr;49(4):1614-6
21270234
PLoS One. 2013;8(3):e59373
23527176
Int J Syst Evol Microbiol. 2006 Jan;56(Pt 1):313-7
16403904
FEMS Yeast Res. 2016 Mar;16(2):fov114
26691882
Rev Argent Microbiol. 2011 Jul-Sep;43(3):176-85
22430989
J Clin Microbiol. 2010 Dec;48(12):4677-9
20881164
J Antimicrob Chemother. 2012 May;67(5):1181-7
22351683
PLoS One. 2011;6(10):e25712
22022438
Mycoses. 2014 Dec;57(12):747-53
25267284
J Clin Microbiol. 2008 Jan;46(1):388-91
18003796
Mycopathologia. 2014 Oct;178(3-4):307-14
25022264
Med Mycol Case Rep. 2013 Oct 25;2:156-8
24432244
Antimicrob Agents Chemother. 2005 Feb;49(2):668-79
15673750
Clin Infect Dis. 2009 Mar 1;48(5):503-35
19191635